Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AxoGen, Inc. stock logo
AXGN
AxoGen
$5.79
-1.5%
$7.86
$3.45
$10.83
$253.08M1.07328,871 shs307,051 shs
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$18.03
-0.7%
$17.37
$8.92
$24.50
$816.76M1.69383,442 shs374,382 shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$127.99
+2.9%
$85.54
$36.42
$129.66
$4.19B1.871.10 million shs1.54 million shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AxoGen, Inc. stock logo
AXGN
AxoGen
-1.53%-12.67%-28.16%-39.69%-34.65%
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-0.72%+2.85%+4.10%+0.50%+1.86%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
+2.85%+39.00%+69.86%+45.11%+75.28%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AxoGen, Inc. stock logo
AXGN
AxoGen
2.4032 of 5 stars
3.53.00.00.01.62.50.6
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.5171 of 5 stars
3.52.00.00.03.02.50.6
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
1.9487 of 5 stars
2.41.00.00.03.02.51.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AxoGen, Inc. stock logo
AXGN
AxoGen
3.00
Buy$10.6784.23% Upside
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
3.00
Buy$23.4029.78% Upside
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.88
Moderate Buy$119.00-7.02% Downside

Current Analyst Ratings

Latest AXGN, BLFS, and TMDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/1/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$100.00 ➝ $130.00
5/1/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$102.00 ➝ $117.00
5/1/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$105.00 ➝ $127.00
5/1/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$95.00 ➝ $120.00
5/1/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$105.00 ➝ $125.00
4/4/2024
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$22.00
3/28/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$95.00
2/28/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$75.00 ➝ $95.00
2/27/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$87.00 ➝ $105.00
2/27/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$92.00 ➝ $105.00
(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AxoGen, Inc. stock logo
AXGN
AxoGen
$159.01M1.59N/AN/A$2.22 per share2.61
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$143.27M5.70N/AN/A$7.67 per share2.35
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$241.62M17.33$0.15 per share874.26$4.20 per share30.47

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AxoGen, Inc. stock logo
AXGN
AxoGen
-$21.72M-$0.50N/AN/AN/A-12.99%-21.96%-10.95%8/5/2024 (Estimated)
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$66.43M-$1.52N/AN/AN/A-46.37%-13.36%-10.83%5/9/2024 (Confirmed)
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-$25.03M-$0.34N/A145.44N/A-3.43%8.29%1.63%8/1/2024 (Estimated)

Latest AXGN, BLFS, and TMDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$0.25N/A+$0.25N/AN/AN/A  
4/30/2024Q1 2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-$0.05$0.35+$0.40$0.35$83.78 million$96.90 million    
3/5/2024Q4 2023
AxoGen, Inc. stock logo
AXGN
AxoGen
-$0.20-$0.09+$0.11-$0.09$42.70 million$42.92 million
2/29/2024Q4 2023
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$0.24-$0.22+$0.02-$0.14$32.70 million$32.73 million
2/26/2024Q4 2023
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-$0.10$0.12+$0.22$0.12$68.49 million$81.20 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AxoGen, Inc. stock logo
AXGN
AxoGen
N/AN/AN/AN/AN/A
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
N/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AxoGen, Inc. stock logo
AXGN
AxoGen
0.71
2.89
2.14
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
0.06
2.86
1.83
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
3.69
9.30
8.49

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
80.29%
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
93.24%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%

Insider Ownership

CompanyInsider Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
7.21%
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.70%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
7.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AxoGen, Inc. stock logo
AXGN
AxoGen
42643.71 million40.55 millionOptionable
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
40945.30 million44.08 millionOptionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
58432.72 million30.42 millionOptionable

AXGN, BLFS, and TMDX Headlines

SourceHeadline
Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Director Sells 15,040 Shares of StockInsider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Director Sells 15,040 Shares of Stock
insidertrades.com - May 4 at 7:32 AM
Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells 56,000 Shares of StockInsider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells 56,000 Shares of Stock
insidertrades.com - May 4 at 7:27 AM
JPMorgan Chase & Co. Raises TransMedics Group (NASDAQ:TMDX) Price Target to $127.00JPMorgan Chase & Co. Raises TransMedics Group (NASDAQ:TMDX) Price Target to $127.00
americanbankingnews.com - May 4 at 5:18 AM
TransMedics Group (NASDAQ:TMDX) Earns Overweight Rating from Piper SandlerTransMedics Group (NASDAQ:TMDX) Earns Overweight Rating from Piper Sandler
americanbankingnews.com - May 4 at 5:18 AM
New York State Common Retirement Fund Increases Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)New York State Common Retirement Fund Increases Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)
marketbeat.com - May 4 at 5:18 AM
TransMedics Group, Inc. to Post Q2 2024 Earnings of $0.10 Per Share, William Blair Forecasts (NASDAQ:TMDX)TransMedics Group, Inc. to Post Q2 2024 Earnings of $0.10 Per Share, William Blair Forecasts (NASDAQ:TMDX)
americanbankingnews.com - May 4 at 1:43 AM
Will TransMedics (TMDX) Gain on Rising Earnings Estimates?Will TransMedics (TMDX) Gain on Rising Earnings Estimates?
zacks.com - May 3 at 1:21 PM
TransMedics Group, Inc. (TMDX) Soars to 52-Week High, Time to Cash Out?TransMedics Group, Inc. (TMDX) Soars to 52-Week High, Time to Cash Out?
zacks.com - May 3 at 10:16 AM
TransMedics Group First Quarter 2024 Earnings: Beats ExpectationsTransMedics Group First Quarter 2024 Earnings: Beats Expectations
finance.yahoo.com - May 3 at 8:31 AM
Should You Think About Buying TransMedics Group, Inc. (NASDAQ:TMDX) Now?Should You Think About Buying TransMedics Group, Inc. (NASDAQ:TMDX) Now?
finance.yahoo.com - May 3 at 8:31 AM
William Blair Analysts Increase Earnings Estimates for TransMedics Group, Inc. (NASDAQ:TMDX)William Blair Analysts Increase Earnings Estimates for TransMedics Group, Inc. (NASDAQ:TMDX)
marketbeat.com - May 3 at 7:28 AM
TransMedics Group (NASDAQ:TMDX) PT Raised to $125.00TransMedics Group (NASDAQ:TMDX) PT Raised to $125.00
americanbankingnews.com - May 3 at 6:42 AM
TransMedics Group (NASDAQ:TMDX) PT Raised to $117.00 at Canaccord Genuity GroupTransMedics Group (NASDAQ:TMDX) PT Raised to $117.00 at Canaccord Genuity Group
americanbankingnews.com - May 3 at 5:18 AM
William Blair Weighs in on TransMedics Group, Inc.s Q3 2025 Earnings (NASDAQ:TMDX)William Blair Weighs in on TransMedics Group, Inc.'s Q3 2025 Earnings (NASDAQ:TMDX)
americanbankingnews.com - May 3 at 4:00 AM
Is TransMedics (TMDX) a Buy as Wall Street Analysts Look Optimistic?Is TransMedics (TMDX) a Buy as Wall Street Analysts Look Optimistic?
zacks.com - May 2 at 10:31 AM
TransMedics Group, Inc. (NASDAQ:TMDX) to Post Q3 2025 Earnings of $0.12 Per Share, William Blair ForecastsTransMedics Group, Inc. (NASDAQ:TMDX) to Post Q3 2025 Earnings of $0.12 Per Share, William Blair Forecasts
marketbeat.com - May 2 at 8:52 AM
TransMedics Group (NASDAQ:TMDX) Price Target Raised to $130.00 at TD CowenTransMedics Group (NASDAQ:TMDX) Price Target Raised to $130.00 at TD Cowen
americanbankingnews.com - May 2 at 5:38 AM
TransMedics Group (NASDAQ:TMDX) Sets New 1-Year High on Better-Than-Expected EarningsTransMedics Group (NASDAQ:TMDX) Sets New 1-Year High on Better-Than-Expected Earnings
americanbankingnews.com - May 2 at 1:18 AM
TransMedics Group Inc.TransMedics Group Inc.
wsj.com - May 1 at 11:55 PM
Why TransMedics Stock Is Soaring TodayWhy TransMedics Stock Is Soaring Today
fool.com - May 1 at 4:11 PM
TransMedics Group (NASDAQ:TMDX) PT Raised to $130.00TransMedics Group (NASDAQ:TMDX) PT Raised to $130.00
marketbeat.com - May 1 at 3:06 PM
Crude Oil Down 3%; ISM Manufacturing PMI Falls In AprilCrude Oil Down 3%; ISM Manufacturing PMI Falls In April
msn.com - May 1 at 1:53 PM
Dow Stages Midday Bounce Ahead of Fed DecisionDow Stages Midday Bounce Ahead of Fed Decision
schaeffersresearch.com - May 1 at 1:53 PM
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), TransMedics Group (TMDX) and Incyte (INCY)Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), TransMedics Group (TMDX) and Incyte (INCY)
markets.businessinsider.com - May 1 at 1:53 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AxoGen logo

AxoGen

NASDAQ:AXGN
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
BioLife Solutions logo

BioLife Solutions

NASDAQ:BLFS
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
TransMedics Group logo

TransMedics Group

NASDAQ:TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.